LINC02322

Across TCGA pan-cancer cohorts, LINC02322 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of LINC02322’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where LINC02322 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02322 is over-expressed in tumor, although a few such as LIHC show the opposite, repressed pattern.

HNSC, BRCA, and LIHC are the cancer types where LINC02322 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC02322 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+0.116	.007	4	view →
BRCA	Female	II,III,IV	+0.096	.003	4	view →
LIHC	Female	III,IV	+0.327	.021	2	view →
LUSC	Male	II,III,IV	+0.135	.017	2	view →
LIHC	Male	II,III,IV	−0.158	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 4 lineages.

LINC02322–HNSC

Open the HNSC breakdown →